Stock Scorecard



Stock Summary for Poseida Therapeutics Inc (PSTX) - $2.67 as of 11/19/2024 10:45:57 AM EST

Total Score

9 out of 30

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for PSTX

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for PSTX

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for PSTX

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for PSTX

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for PSTX (27 out of 90)

Stock Price Rating (Max of 10) 3
Historical Stock Price Rating (Max of 10) 5
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 3
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 5
Trading Volume (Max of 10) 5
Price to Earnings (Max of 10) 0

Latest News for for PSTX

Poseida Therapeutics, Inc. ( PSTX ) Is Up 24.70% in One Week: What You Should Know 11/12/2024 5:00:00 PM
Poseida Therapeutics, Inc. ( PSTX ) Q3 Earnings and Revenues Beat Estimates 11/7/2024 10:55:00 PM
MaxCyte Appoints Cynthia Collins to its Board of Directors - DermTech ( OTC:DMTKQ ) , Certara ( NASDAQ:CERT ) 10/15/2024 12:05:00 PM
Poseida Therapeutics, Inc. ( PSTX ) Reports Q2 Loss, Tops Revenue Estimates 8/5/2024 9:55:00 PM
Are You Looking for a Top Momentum Pick? Why Poseida Therapeutics, Inc. ( PSTX ) is a Great Choice 7/19/2024 4:00:00 PM
Akoya Biosciences ( AKYA ) Reports Q1 Loss, Lags Revenue Estimates 5/13/2024 9:35:00 PM
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology 5/1/2024 1:00:00 PM
Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus 4/17/2024 1:00:00 PM
Adaptimmune ( ADAP ) Down on End of Collaboration With Roche 4/15/2024 6:12:00 PM
Gene therapy market size to grow by USD 4.61 billion from 2022 to 2027, North America is estimated to contribute 39 ... - PR Newswire 3/18/2024 9:36:00 AM

Financial Details for PSTX

Company Overview

Ticker PSTX
Company Name Poseida Therapeutics Inc
Country USA
Description Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for patients with high unmet medical needs. The company is headquartered in San Diego, California.
Sector Name LIFE SCIENCES
Industry Name BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Most Recent Quarter 9/30/2024
Next Earnings Date N/A

Stock Price History

Last Day Price 2.67
Price 4 Years Ago 10.97
Last Day Price Updated 11/19/2024 10:45:57 AM EST
Last Day Volume 412,949
Average Daily Volume 516,922
52-Week High 4.27
52-Week Low 1.87
Last Price to 52 Week Low 42.78%

Valuation Measures

Trailing PE N/A
Industry PE 120.49
Sector PE 40.32
5-Year Average PE -4.16
Free Cash Flow Ratio 1.13
Industry Free Cash Flow Ratio 15.59
Sector Free Cash Flow Ratio 27.97
Current Ratio Most Recent Quarter 3.20
Total Cash Per Share 2.37
Book Value Per Share Most Recent Quarter 0.90
Price to Book Ratio 3.08
Industry Price to Book Ratio 5.50
Sector Price to Book Ratio 20.88
Price to Sales Ratio Twelve Trailing Months 1.73
Industry Price to Sales Ratio Twelve Trailing Months 20.11
Sector Price to Sales Ratio Twelve Trailing Months 7.11
Analyst Buy Ratings 3
Analyst Strong Buy Ratings 2

Share Statistics

Total Shares Outstanding 97,465,000
Market Capitalization 260,231,550
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -92.81%
Reported EPS 12 Trailing Months -0.63
Reported EPS Past Year -0.36
Reported EPS Prior Year -1.39
Net Income Twelve Trailing Months -60,729,000
Net Income Past Year -123,400,000
Net Income Prior Year -64,000,000
Quarterly Revenue Growth YOY 667.00%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months 0.28

Balance Sheet

Total Cash Most Recent Quarter 230,900,000
Total Cash Past Year 212,200,000
Total Cash Prior Year 282,500,000
Net Cash Position Most Recent Quarter 172,104,000
Net Cash Position Past Year 153,610,000
Long Term Debt Past Year 58,590,000
Long Term Debt Prior Year 58,250,000
Total Debt Most Recent Quarter 58,796,000
Equity to Debt Ratio Past Year 0.64
Equity to Debt Ratio Most Recent Quarter 0.60
Total Stockholder Equity Past Year 103,701,000
Total Stockholder Equity Prior Year 187,595,000
Total Stockholder Equity Most Recent Quarter 87,211,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -17,159,000
Free Cash Flow Per Share Twelve Trailing Months -0.18
Free Cash Flow Past Year -95,266,000
Free Cash Flow Prior Year -30,696,000

Options

Put/Call Ratio 0.00
Has Options False
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.16
MACD Signal 0.10
20-Day Bollinger Lower Band 2.17
20-Day Bollinger Middle Band 2.90
20-Day Bollinger Upper Band 3.62
Beta 0.54
RSI 47.42
50-Day SMA 3.39
150-Day SMA 0.00
200-Day SMA 4.67

System

Modified 11/19/2024 10:46:43 AM EST